Skip to content
ETEN
Findshops
Science & Health

CBD and Autism: What Do the 2026 Studies in Children Show?

Illustrative laboratory research, rather than the children's study

Could CBD help some associated difficulties in autistic children? Research has produced some encouraging findings, but evidence remains limited and inconsistent. CBD is not a proven autism treatment, and cannabinoids should not be given to a child without consulting their treating clinician.

What is actually being studied?

Autism is a neurodevelopmental difference, rather than an infection or single symptom that one medicine can “cure”. Research mainly examines associated problems such as anxiety, irritability or sleep difficulties. These are distinct outcomes; improvement in one does not establish changes to core autistic traits.

Researchers have used different preparations: pure CBD in some studies and extracts containing CBD and THC in others. Their findings are not interchangeable, and doses and follow-up periods also vary.

A 2026 trial did not confirm its primary outcome

A randomised, double-blind crossover study in Autism Research involved 29 autistic children aged 5–12. It compared CBD oil with terpenes against placebo over two 12-week treatment periods.

The primary measure, an overall social communication rating, did not improve significantly more with CBD than placebo. Some secondary measures changed, including reduced anxiety and parental stress. The small sample and unmet primary endpoint prevent a firm conclusion about efficacy.

Scientist working with a microscope in a laboratory
Illustrative research photograph. Photo: Jahra Tasfia Reza / Pexels; this does not depict the study.

What do broader reviews show?

A 2026 systematic review covered 12 studies, including four randomised controlled trials. One CBD–THC extract study found positive results on some behavioural measures, but several other outcomes did not differ from placebo. Authors considered evidence quality limited and called for larger, better-standardised trials.

Another 2026 review covering autism and other neurodevelopmental conditions reached a similar conclusion: some symptoms may warrant further investigation, but current data do not support routine clinical use.

What risks are possible?

CBD is not automatically risk-free. Studies have described fatigue, appetite changes, sleep problems and digestive symptoms. Cannabinoids can interact with other medicines. Some extracts also contained THC, with separate psychoactive and other risks.

Clinically supervised trials must be distinguished from cannabinoid products sold online. Composition, quality controls and legal status can differ. A foreign trial does not establish that the same product is permitted or appropriate for a child in Estonia.

What should parents know?

Anxiety, behavioural difficulties, sleep or other symptoms disrupting a child’s life should be discussed with their clinician or relevant specialist. CBD and cannabis extracts should not replace evidence-based support, educational adjustments and healthcare.

For wider anxiety research, see CBD for Anxiety: What Does the Science Actually Say? (in Estonian).

Sources

Share article
REKLAAMIPIND
Your ad here

Advertising space available.

Get in touch ↗

Lisa kommentaar

Your email address will not be published. Required fields are marked *